References
- Berbari EF, Steckelberg JM, Osmon DR. Osteomyelitis. In: Mandell GL, Douglas RG, Dolin R, editors. Principles and practice of infectious diseases, 7th edn. New York: Churchill Livingstone; 2010. pp. 1457–65.
- Lazzarini L, Mader JT, Calhoun JH. Osteomyelitis in long bones. J Bone Joint Surg Am 2004;86:2305–18.
- Lew DP, Waldvogel FA. Osteomyelitis. Lancet 2004;364: 369–79.
- Halliwell B. Free radicals, antioxidants and human disease: curiosity, cause, or consequence?Lancet 1994;344: 721–4.
- Gutteridge JMC. Free radicals in disease processes: a complication of cause and consequence. Free Radical Res Commun 1993;19:141–58.
- Goldenberg DL. Septic arthritis. Lancet 1998; 351: 197–202.
- Shirtliff ME, Mader JT. Acute septic arthritis. Clin Microbiol Rev 2002;15:527–44.
- Nade S. Septic arthritis. Best Pract Res Clin Rheumatol 2003;17:183–200.
- Ozols, J. Isolation and complete covalent structure of liver microsomal paraoxonase. Biochem J 1999;338:265–72.
- Rozenberg O, Rosenblat M, Coleman R, Shih DM, Aviram M. Paraoxonase (PON1) deficiency is associated with increased macrophage oxidative stress: studies in PON1-knock out mice. Free Radical Biol Med 2003;34:774–84.
- Kilic SS, Aydin S, Kilic N, Erman F, Aydin S, Celik I. Serum arylesterase and paraoxonase activity in patients with chronic hepatitis. World J Gastroenterol 2005;11:7351–4.
- Baskol G, Demir H, Baskol M, Kilic E, Ates F, Kocer D, Muhtaroglu S. Assessment of paraoxonase 1 activity and malondialdehyde levels in patients with rheumatoid arthritis. Clin Biochem 2005;38:951–5.
- Soran N, Altindag O, Cakir H, Celik H, Demirkol A, Aksoy N. Assessment of paraoxonase activities in patients with knee osteoarthritis. Redox Report 2008;13(5):194–8.
- Girotti AW. Lipid hydroperoxide generation, turnover, and Vector action in biological systems. J Lipid Res 1998;39: 1529–42.
- Vassiliev V, Harris ZL, Zatta P. Ceruloplasmin in neurodegenerative diseases. Brain Res Rev 2005;49:633–40.
- Eckerson HW, Wyte MC, La Du BN. The human serum paraoxonase/arylesterase polymorphism. Am J Hum GCnet 1983;35:1126–38.
- Haagen L, Brock A. A new automated method for phenotyping arylesterase (E.C.3.1.1.2.) based upon inhibition of enzymatic hydrolysis of 4-nitrophenyl acetate by phenyl acetate. Eur J Clin Chem Clin Biochem 1992;30:391–5.
- Gorog P, Kotak DC, Kovacs IB. Simple and specific test for measuring lipid peroxides in plasma. J Clin Pathol 1991;44:765–7.
- Ellman GL. Tissue sulfhydryl groups. Arch Biochem Biophys 1959;82:70–7.
- Hu ML, Louie S, Cross CE, Motchnik P, Halliwell B. Antioxidant protection against hypochlorous acid in human plasma. J Lab Clin Med 1993;121:257–62.
- Erel O. Automated measurement of serum ferroxidase activity. Clin Chem 1998;44:2313–9.
- Kumon Y, Nakauchi Y, Suehiro T, Shiinoki T, Tanimoto N, Inoue M, Nakamura T, Hashimoto K, Sipe JD. Proinflammatory cytokines but not acute phase serum amyloid A or C-reactive protein, down regulate paraoxonase 1 (PON1) expression by Hep G2. Amyloid 2002;9:160–4.
- Van Lenten BJ, Wagner AC, Nayak DP, Hama S, Navab M, Fogelman AM. High-density lipoprotein loses its anti-inflammatory properties during acute influenza a infection. Circulation 2001;103:2283–8.
- Durrinton PN, Mackness B, Mackness MI. Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol 2001;21:473– 80.
- Brady BA, Leid JG, Costerton JW, Shirtliff ME. Osteomyelitis: Clinical overview and mechanisms of infection persistence. Clin Microbiol Newsletter 2006;28(9):65–72.
- Erel O. A novel automated method to measure total antioxidant response against potent free radical reactions. Clin Biochem 2004;37:112–9.
- Gur M, Aslan M, Yildiz A, Demirbag R, Yilmaz R, Selek S, Erel O, Ozdogru I. Paraoxonase and arylesterase activities in coronary artery disease. Eur J Clin Invest 2006;36: 779–87.
- Leitinger N. Cholesteryl ester oxidation products in atherosclerosis. Mol Aspects Med 2003;24:239–50.
- Marsillach J, Camps J, Ferré N, Beltran R, Rull A, Mackness B, Mackness M, Joven J. Paraoxonase-1 is related to inflammation, fibrosis and PPAR delta in experimental liver disease. BMC Gastroenterology 2009;9:3.
- Mackness B, Durrington PN, Mackness MI. Polymorphisms of paraoxonase genes and low-density lipoprotein lipid peroxidation. Lancet 1999;353:468–9.
- Agachan B, Yilmaz H, Ergen A, Karaali ZE, Isbir T. Paraoxonase (PON1) 55 and 192 polymorphism and its effects to oxidant-antioxidant system in Turkish patients with type 2 diabetes mellitus. Physiol Res 2005;54:287–93.